<?xml version="1.0" encoding="UTF-8"?>
<p>TTO has gained much interest from scientists, physicians and consumers because of its broad-spectrum antimicrobial activity against a variety of bacteria including MRSA, and has long been used as an antibacterial agent for variety of skin conditions by the Aboriginal and mainstream Australian communities for over a century with good safety and efficacy data [
 <xref rid="B87-antibiotics-09-00909" ref-type="bibr">87</xref>,
 <xref rid="B96-antibiotics-09-00909" ref-type="bibr">96</xref>]. The activity of TTO against various Gram-positive bacteria has been well documented [
 <xref rid="B86-antibiotics-09-00909" ref-type="bibr">86</xref>]. It is particularly effective at low concentrations against impetigo causing bacteria (minimum inhibitory concentration (MIC): 0.5–1.25 and minimum bactericidal concentration (MBC): 1–2% (
 <italic>v</italic>/
 <italic>v</italic>) vs. 
 <italic>S. aureus</italic>; MIC: 0.04–0.35 and MBC: 0.5% (
 <italic>v</italic>/
 <italic>v</italic>) vs. MRSA), and MIC: 0.12–2 and MBC: 0.25–4% (
 <italic>v</italic>/
 <italic>v</italic>) vs. 
 <italic>S. pyogenes</italic> [
 <xref rid="B86-antibiotics-09-00909" ref-type="bibr">86</xref>,
 <xref rid="B87-antibiotics-09-00909" ref-type="bibr">87</xref>], indicating its promise as a topical antimicrobial agent for impetigo.
</p>
